Instruction 1(b)

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT	OF CHA	NGES IN	BENEFICIAL	OWNERSHIP

OMB APP	ROVAL
OMB Number:	3235-0287
Estimated average t	ourden
hours per response:	0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* OSBORNE DAVID W					2. Issuer Name and Ticker or Trading Symbol Arcutis Biotherapeutics, Inc. [ARQT]								ck all applic Directo Officer	cable) or (give title	g Pers	son(s) to Iss 10% Ov Other (s	vner	
(Last) (First) (Middle) C/O ARCUTIS BIOTHERAPEUTICS, INC. 3027 TOWNSGATE ROAD, SUITE 300				3. Date of Earliest Transaction (Month/Day/Year) 03/02/2023									below) below) Chief Technical Officer					
(Street) WESTLAKE VILLAGE (City) (State) (Zip)					4. If Amendment, Date of Original Filed (Month/Day/Year)						Line)	. Individual or Joint/Group Filing (Check Applicable ine) X Form filed by One Reporting Person Form filed by More than One Reporting Person						
		Tab	le I - Non-	Derivat	ive S	ecurities	s Ac	quired,	Dis	posed c	f, or B	enef	ficially	/ Owned				
Date			2. Transact Date (Month/Day	Execution Date,		3. Transaction Code (Instr. 8) 4. Securities Acquired (A Disposed Of (D) (Instr. 3, 5)			5. Amou Securitie Beneficia Owned F	es Formally (D) (Following (I) (I		rm: Direct or Indirect (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)					
							Code	v	Amount	(A) or P		Price	Transact (Instr. 3	tion(s)			(111341. 4)	
Common Stock 03/02/			03/02/2	2/2023		A		14,900	14,900 ⁽¹⁾ A		\$0	269,544			D			
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
Derivative Conversion Date Execution Security or Exercise (Month/Day/Year) if any		3A. Deemed Execution Da if any (Month/Day/Y	Date, Transaction Code (Instr.		n of		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		curity	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)		
				Cod	e V	(A)	(D)	Date Exercisab		Expiration Date	Title	or Nu of	ımber					
Stock Option (Right to Buy)	\$15.82	03/02/2023		A		39,500		(2)	C	03/02/2033	Commo Stock	n 39	9,500	\$0	39,500)	D	

Explanation of Responses:

- 1. Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon vesting. 25% of the RSUs vest annually on March 2 of each year, beginning March 2, 2024, subject to the Reporting Person's continued service to the Issuer
- 2. 1/48th of the shares subject to the option vest on each monthly anniversary measured from March 2, 2023 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer.

/s/ Scott Burrows, as Attorney-

in-Fact for David W. Osborne,

Ph.D.

** Signature of Reporting Person Date

03/06/2023

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.